David T. Rodgers
Affiliations: | California Institute for Biomedical Research |
Google:
"David Rodgers"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Travis S. Young | post-doc | 2013- | California Institute for Biomedical Research |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Raj D, Yang MH, Rodgers D, et al. (2018) Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut |
| Laborda E, Mazagova M, Shao S, et al. (2017) Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia. International Journal of Molecular Sciences. 18 |
| Yu S, Pearson A, Lim R, et al. (2017) P-262 A PDE4 Inhibitor-antibody Conjugate for Treating Ulcerative Colitis Inflammatory Bowel Diseases. 23 |
| Eason RJ, Bell KS, Marshall FA, et al. (2016) The helminth product, ES-62 modulates dendritic cell responses by inducing the selective autophagolysosomal degradation of TLR-transducers, as exemplified by PKCδ. Scientific Reports. 6: 37276 |
| Yu S, Pearson AD, Lim RK, et al. (2016) Targeted delivery of an anti-inflammatory PDE4 inhibitor to immune cells via an antibody-drug conjugate. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Cao Y, Rodgers DT, Du J, et al. (2016) Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer. Angewandte Chemie (International Ed. in English). 55: 7520-4 |
| Janicova L, Rzepecka J, Rodgers DT, et al. (2016) Testing small molecule analogues of the Acanthocheilonema viteae immunomodulator ES-62 against clinically relevant allergens. Parasite Immunology. 38: 340-51 |
| Rodgers DT, Mazagova M, Hampton EN, et al. (2016) Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proceedings of the National Academy of Sciences of the United States of America. 113: E459-68 |
| Ma JS, Kim JY, Kazane SA, et al. (2016) Versatile strategy for controlling the specificity and activity of engineered T cells. Proceedings of the National Academy of Sciences of the United States of America. 113: E450-8 |
| Rodgers DT, Pineda MA, Suckling CJ, et al. (2015) Drug-like analogues of the parasitic worm-derived immunomodulator ES-62 are therapeutic in the MRL/Lpr model of systemic lupus erythematosus. Lupus |